Diagnosis and management of hymenoptera venom allergy: British Society for Allergy and Clinical Immunology (BSACI) guidelines

Clinical and Experimental Allergy

Volumn 41, Issue 9, 2011, Pages 1201-1220

  Krishna, M T ^a   Ewan, P W ^b   Diwakar, L ^a   Durham, S R ^c   Frew, A J ^d   Leech, S C ^e   Nasser, S M ^b  

^a BIRMINGHAM HEARTLANDS HOSPITAL   (United Kingdom)

^b CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

^d BRIGHTON GENERAL HOSPITAL   (United Kingdom)

^e KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

blocker; ACE inhibitor; Anaphylaxis; Baseline tryptase; Bee; Hornet; Hymenoptera; IgE; Immunotherapy; Venom; Wasp

Indexed keywords

ADRENALIN; ANTIHISTAMINIC AGENT; BEE VENOM; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYMENOPTERA VENOM; IMMUNOGLOBULIN E; IMMUNOGLOBULIN E ANTIBODY; OMALIZUMAB; PHARMALGEN; TRYPTASE; WASP VENOM;

ANGIONEUROTIC EDEMA; ARTICLE; CLINICAL FEATURE; DIAGNOSTIC ERROR; DIAGNOSTIC TEST; DRUG DOSE INCREASE; DRUG DOSE REGIMEN; DRUG HYPERSENSITIVITY; HUMAN; IMMUNOTHERAPY; INSECT ALLERGY; MAINTENANCE DRUG DOSE; MASTOCYTOSIS; NONHUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; PRURITUS; RISK FACTOR; TREATMENT INDICATION; URTICARIA; VENOM IMMUNOTHERAPY;

ADULT; ANIMALS; ARTHROPOD VENOMS; CHILD; DESENSITIZATION, IMMUNOLOGIC; HUMANS; HYMENOPTERA; HYPERSENSITIVITY; RISK FACTORS;

EID: 80051718501     PISSN: 09547894     EISSN: 13652222     Source Type: Journal    
DOI: 10.1111/j.1365-2222.2011.03788.x     Document Type: Article

References (154)

1. BSACI working party. Position paper on allergen immunotherapy. Report of a BSACI working party. January-October 1992. Clin Exp Allergy 1993; 23 (Suppl. 3):1-44.
2. Antonicelli L, Bilo MB, Bonifazi F. Epidemiology of Hymenoptera allergy. Curr Opin Allergy Clin Immunol 2002; 2:341-6.
3. Bilo BM, Rueff F, Mosbech H, Bonifazi F, Oude-Elberink JN. Diagnosis of Hymenoptera venom allergy. Allergy 2005; 60:1339-49.
4. Golden DB, Marsh DG, Kagey-Sobotka A et al. Epidemiology of insect venom sensitivity. JAMA 1989; 262:240-4.
5. Grigoreas C, Galatas ID, Kiamouris C, Papaioannou D. Insect-venom allergy in Greek adults. Allergy 1997; 52:51-7.
6. Incorvaia C, Mauro M, Pastorello EA. Hymenoptera stings in conscripts. Allergy 1997; 52:680-1.
7. Fernandez J, Blanca M, Soriano V, Sanchez J, Juarez C. Epidemiological study of the prevalence of allergic reactions to Hymenoptera in a rural population in the Mediterranean area. Clin Exp Allergy 1999; 29:1069-74.
8. Fernandez J, Soriano V, Mayorga L, Mayor M. Natural history of Hymenoptera venom allergy in Eastern Spain. Clin Exp Allergy 2005; 35:179-85.
9. Novembre E, Cianferoni A, Bernardini R et al. Epidemiology of insect venom sensitivity in children and its correlation to clinical and atopic features. Clin Exp Allergy 1998; 28:834-8.
10. Onbasi K, Onbasi O, Eminbeyli L, Kaynak C. Prevalence and alternative therapy methods for bee and wasp allergy in Van. Allergy 2008; 63:246-7.
11. Muller UR. Bee venom allergy in beekeepers and their family members. Curr Opin Allergy Clin Immunol 2005; 5:343-7.
12. Pumphrey RS. Lessons for management of anaphylaxis from a study of fatal reactions. Clin Exp Allergy 2000; 30:1144-50.
13. Pumphrey RS. Fatal anaphylaxis in the UK, 1992-2001. Novartis Found Symp 2004; 257:116-28.
14. Pucci S, Antonicelli L, Bilo MB, Garritani MS, Bonifazi F. Shortness of interval between two stings as risk factor for developing Hymenoptera venom allergy. Allergy 1994; 49:894-6.
15. Golden DB. Insect sting allergy and venom immunotherapy: a model and a mystery. J Allergy Clin Immunol 2005; 115:439-47.
16. Golden DB. Practical considerations in venom immunotherapy. Allergy Asthma Proc 1997; 18:79-83.
17. Day JH, Buckeridge DL, Welsh AC. Risk assessment in determining systemic reactivity to honeybee stings in sting-threatened individuals. J Allergy Clin Immunol 1994; 93:691-705.
18. Golden DB, Breisch NL, Hamilton RG et al. Clinical and entomological factors influence the outcome of sting challenge studies. J Allergy Clin Immunol 2006; 117:670-5.
19. Schuberth KC, Lichtenstein LM, Kagey-Sobotka A, Szklo M, Kwiterovich KA, Valentine MD. An epidemiologic study of insect allergy in children. I. Characteristics of the disease. J Pediatr 1982; 100:546-51.
20. Muller UR. Cardiovascular disease and anaphylaxis. Curr Opin Allergy Clin Immunol 2007; 7:337-41.
21. Stumpf JL, Shehab N, Patel AC. Safety of Angiotensin-converting enzyme inhibitors in patients with insect venom allergies. Ann Pharmacother 2006; 40:699-703.
22. Rueff F, Przybilla B, Bilo MB et al. Predictors of severe systemic anaphylactic reactions in patients with Hymenoptera venom allergy: importance of baseline serum tryptase-a study of the European Academy of Allergology and Clinical Immunology Interest Group on Insect Venom Hypersensitivity. J Allergy Clin Immunol 2009; 124:1047-54.
23. Haeberli G, Bronnimann M, Hunziker T, Muller U. Elevated basal serum tryptase and hymenoptera venom allergy: relation to severity of sting reactions and to safety and efficacy of venom immunotherapy. Clin Exp Allergy 2003; 33:1216-20.
24. Ludolph-Hauser D, Rueff F, Fries C, Schopf P, Przybilla B. Constitutively raised serum concentrations of mast-cell tryptase and severe anaphylactic reactions to Hymenoptera stings. Lancet 2001; 357:361-2.
25. Gonzalez de Olano D, varez-Twose I, Esteban-Lopez MI et al. Safety and effectiveness of immunotherapy in patients with indolent systemic mastocytosis presenting with Hymenoptera venom anaphylaxis. J Allergy Clin Immunol 2008; 121:519-26.
26. Wagner N, Fritze D, Przybilla B, Hagedorn M, Rueff F. Fatal anaphylactic sting reaction in a patient with mastocytosis. Int Arch Allergy Immunol 2008; 146:162-3.
27. Fernandez J. Distribution of vespid species in Europe. Curr Opin Allergy Clin Immunol 2004; 4:319-24.
28. Mueller U, Reisman R, Wypych J et al. Comparison of vespid venoms collected by electrostimulation and by venom sac extraction. J Allergy Clin Immunol 1981; 68:254-61.
29. Reisman RE, Mueller U, Wypych J, Elliott W, Arbesman CE. Comparison of the allergenicity and antigenicity of yellow jacket and hornet venoms. J Allergy Clin Immunol 1982; 69:268-74.
30. Hoffman DR. Allergens in hymenoptera venom. VI. Cross reactivity of human IgE antibodies to the three vespid venoms and between vespid and paper wasp venoms. Ann Allergy 1981; 46:304-9.
31. Reisman RE, Wypych JI, Mueller UR, Grant JA. Comparison of the allergenicity and antigenicity of Polistes venom and other vespid venoms. J Allergy Clin Immunol 1982; 70:281-7.
32. Hoffman DR. Allergens in Hymenoptera venom. XXV: the amino acid sequences of antigen 5 molecules and the structural basis of antigenic cross-reactivity. J Allergy Clin Immunol 1993; 92:707-16.
33. King TP, Lu G, Gonzalez M, Qian N, Soldatova L. Yellow jacket venom allergens, hyaluronidase and phospholipase: sequence similarity and antigenic cross-reactivity with their hornet and wasp homologs and possible implications for clinical allergy. J Allergy Clin Immunol 1996; 98:588-600.
34. Wypych JI, Abeyounis CJ, Reisman RE. Analysis of differing patterns of cross-reactivity of honeybee and yellow jacket venom-specific IgE: use of purified venom fractions. Int Arch Allergy Appl Immunol 1989; 89:60-6.
35. Caruso B, Bonadonna P, Severino MG et al. Evaluation of the IgE cross-reactions among vespid venoms. A possible approach for the choice of immunotherapy. Allergy 2007; 62:561-4.
36. Stapel SO, Waanders-Lijster de RJ, van Toorenenbergen AW, de GH. Allergy to bumblebee venom. II. IgE cross-reactivity between bumblebee and honeybee venom. Allergy 1998; 53:769-77.
37. Hoffman DR, Jacobson RS. Allergens in Hymenoptera venom. XXVII: bumblebee venom allergy and allergens. J Allergy Clin Immunol 1996; 97:812-21.
38. Egner W, Ward C, Brown DL, Ewan PW. The frequency and clinical significance of specific IgE to both wasp (Vespula) and honey-bee (Apis) venoms in the same patient. Clin Exp Allergy 1998; 28:26-34.
39. Hemmer W. [Cross-reactivity to honeybee and wasp venom]. Hautarzt 2008; 59:194-9.
40. Jappe U, Raulf-Heimsoth M, Hoffmann M, Burow G, Hubsch-Muller C, Enk A. In vitro hymenoptera venom allergy diagnosis: improved by screening for cross-reactive carbohydrate determinants and reciprocal inhibition. Allergy 2006; 61:1220-9.
41. Muller UR, Johansen N, Petersen AB, Fromberg-Nielsen J, Haeberli G. Hymenoptera venom allergy: analysis of double positivity to honey bee and Vespula venom by estimation of IgE antibodies to species-specific major allergens Api m1 and Ves v5. Allergy 2009; 64:543-8.
42. Severino M, Bonadonna P, Passalacqua G. Large local reactions from stinging insects: from epidemiology to management. Curr Opin Allergy Clin Immunol 2009; 9:334-7.
43. Mauriello PM, Barde SH, Georgitis JW, Reisman RE. Natural history of large local reactions from stinging insects. J Allergy Clin Immunol 1984; 74:494-8.
44. Hunt KJ, Valentine MD, Sobotka AK, Benton AW, Amodio FJ, Lichtenstein LM. A controlled trial of immunotherapy in insect hypersensitivity. N Engl J Med 1978; 299:157-61.
45. Valentine MD, Schuberth KC, Kagey-Sobotka A et al. The value of immunotherapy with venom in children with allergy to insect stings. N Engl J Med 1990; 323:1601-3.
46. Settipane GA, Chafee FH. Natural history of allergy to Hymenoptera. Clin Allergy 1979; 9:385-90.
47. Reisman RE, Dvorin DJ, Randolph CC, Georgitis JW. Stinging insect allergy: natural history and modification with venom immunotherapy. J Allergy Clin Immunol 1985; 75:735-40.
48. Novembre E, Cianferoni A, Bernardini R et al. Anaphylaxis in children: clinical and allergologic features. Pediatrics 1998; 101:E8.
49. Settipane GA, Boyd GK. Prevalence of bee sting allergy in 4, 992 boy scouts. Acta Allergol 1970; 25:286-91.
50. Barnard JH. Studies of 400 Hymenoptera sting deaths in the United States. J Allergy Clin Immunol 1973; 52:259-64.
51. Golden DB, Kagey-Sobotka A, Norman PS, Hamilton RG, Lichtenstein LM. Outcomes of allergy to insect stings in children, with and without venom immunotherapy. N Engl J Med 2004; 351:668-74.
52. Gruchalla RS. Immunotherapy in allergy to insect stings in children. N Engl J Med 2004; 351:707-9.
53. Arcieri ES, Franca ET, de Oliveria HB, De Abreu FL, Ferreira MA, Rocha FJ. Ocular lesions arising after stings by hymenopteran insects. Cornea 2002; 21:328-30.
54. Brumlik J. Myasthenia gravis associated with wasp sting. JAMA 1976; 235:2120-1.
55. Burke DM, Jellinek HL. Nearly fatal case of Schoenlein-Henoch syndrome following insect bite. AMA Am J Dis Child 1954; 88:772-4.
56. Chao YW, Yang AH, Ng YY, Yang WC. Acute interstitial nephritis and pigmented tubulopathy in a patient after wasp stings. Am J Kidney Dis 2004; 43:e15-e19.
57. Freye HB, Ehrlich B. Acute myocardial infarction following hymenoptera envenomation. Allergy Proc 1989; 10:119-26.
58. Gale AN. Insect-sting encephalopathy. Br Med J (Clin Res Ed) 1982; 284:20-1.
59. Lin CC, Chang MY, Lin JL. Hornet sting induced systemic allergic reaction and large local reaction with bulle formation and rhabdomyolysis. J Toxicol Clin Toxicol 2003; 41:1009-11.
60. Mukhopadhyay A, Fong KF, Lim TK. Diffuse alveolar haemorrhage: a rare reaction to insect sting. Respirology 2002; 7:157-9.
61. Tanphaichitr VS, Tuchinda M. Severe thrombocytopenic purpura following a bee sting. Ann Allergy 1982; 49:229-31.
62. Franken HH, Dubois AE, Minkema HJ, van der HS, de Monchy JG. Lack of reproducibility of a single negative sting challenge response in the assessment of anaphylactic risk in patients with suspected yellow jacket hypersensitivity. J Allergy Clin Immunol 1994; 93:431-6.
63. Hunt KJ, Valentine MD, Sobotka AK, Lichtenstein LM. Diagnosis of allergy to stinging insects by skin testing with Hymenoptera venoms. Ann Intern Med 1976; 85:56-9.
64. Valentine MD. Allergy to stinging insects. Ann Allergy 1993; 70:427-32.
65. Dreborg S, Frew AJ. Position Paper: allergen standardization and skin tests. Allergy 1993; 48:49-54.
66. Bonadonna P, Perbellini O, Passalacqua G et al. Clonal mast cell disorders in patients with systemic reactions to Hymenoptera stings and increased serum tryptase levels. J Allergy Clin Immunol 2009; 123:680-6.
67. Metcalfe DD, Schwartz LB. Assessing anaphylactic risk? Consider mast cell clonality. J Allergy Clin Immunol 2009; 123:687-8.
68. Potier A, Lavigne C, Chappard D et al. Cutaneous manifestations in Hymenoptera and Diptera anaphylaxis: relationship with basal serum tryptase. Clin Exp Allergy 2009; 39:717-25.
69. Bonadonna P, Zanotti R, Caruso B et al. Allergen specific immunotherapy is safe and effective in patients with systemic mastocytosis and Hymenoptera allergy. J Allergy Clin Immunol 2008; 121:256-7.
70. Sturm GJ, Heinemann A, Schuster C et al. Influence of total IgE levels on the severity of sting reactions in Hymenoptera venom allergy. Allergy 2007; 62:884-9.
71. Ebo DG, Hagendorens MM, Schuerwegh AJ et al. Flow-assisted quantification of in vitro activated basophils in the diagnosis of wasp venom allergy and follow-up of wasp venom immunotherapy. Cytometry B Clin Cytom 2007; 72:196-203.
72. Erdmann SM, Sachs B, Kwiecien R, Moll-Slodowy S, Sauer I, Merk HF. The basophil activation test in wasp venom allergy: sensitivity, specificity and monitoring specific immunotherapy. Allergy 2004; 59:1102-9.
73. Sainte-Laudy J, Sabbah A, Drouet M, Lauret MG, Loiry M. Diagnosis of venom allergy by flow cytometry. Correlation with clinical history, skin tests, specific IgE, histamine and leukotriene C4 release. Clin Exp Allergy 2000; 30:1166-71.
74. Sturm GJ, Bohm E, Trummer M, Weiglhofer I, Heinemann A, Aberer W. The CD63 basophil activation test in Hymenoptera venom allergy: a prospective study. Allergy 2004; 59:1110-7.
75. Kosnik M, Silar M, Bajrovic N, Music E, Korosec P. High sensitivity of basophils predicts side-effects in venom immunotherapy. Allergy 2005; 60:1401-6.
76. Eberlein-Konig B, Schmidt-Leidescher C, Behrendt H, Ring J. Predicting side-effects in venom immunotherapy by basophil activation? Allergy 2006; 61:897.
77. Green-Graif Y, Ewan PW. Diagnostic value of the skin-prick test and RAST assay in insect sting allergy. Clin Allergy 1987; 17:431-8.
78. Ewan P, Deighton J, Lachmann PJ. Detection of IgE antibody to venom antigens by Western blotting in patients with negative RAST. Allergy 1993; 48:116; Abstract.
79. Golden DB, Kagey-Sobotka A, Norman PS, Hamilton RG, Lichtenstein LM. Insect sting allergy with negative venom skin test responses. J Allergy Clin Immunol 2001; 107:897-901.
80. Wicher K, Reisman RE, Wypych J et al. Comparison of the venom immunogenicity of various species of yellow jackets (genus Vespula). J Allergy Clin Immunol 1980; 66:244-9.
81. Hoffman DR. Allergens in Hymenoptera venom. XVI: studies of the structures and cross-reactivities of vespid venom phospholipases. J Allergy Clin Immunol 1986; 78:337-43.
82. Blanca M, Garcia F, Miranda A et al. Determination of IgE antibodies to Polistes dominulus, Vespula germanica and Vespa crabro in sera of patients allergic to vespids. Allergy 1991; 46:109-14.
83. Hamilton RG, Wisenauer JA, Golden DB, Valentine MD, Adkinson NF Jr Selection of Hymenoptera venoms for immunotherapy on the basis of patient's IgE antibody cross-reactivity. J Allergy Clin Immunol 1993; 92:651-9.
84. Muller U, Thurnheer U, Patrizzi R, Spiess J, Hoigne R. Immunotherapy in bee sting hypersensitivity. Bee venom versus wholebody extract. Allergy 1979; 34:369-78.
85. Gillman SA, Cummins LH, Kozak PP Jr, Hoffman DR. Venom immunotherapy: comparison of "rush" vs "conventional" schedules. Ann Allergy 1980; 45:351-4.
86. Mosbech H, Malling HJ, Biering I et al. Immunotherapy with yellow jacket venom. A comparative study including three different extracts, one adsorbed to aluminium hydroxide and two unmodified. Allergy 1986; 41:95-103.
87. Muller U, Helbling A, Berchtold E. Immunotherapy with honeybee venom and yellow jacket venom is different regarding efficacy and safety. J Allergy Clin Immunol 1992; 89:529-35.
88. Urbanek R, Karitzky D, Forster J. Hyposensitisation treatment with pure bee venom (author's translation). Dtsch Med Wochenschr 1978; 103:1656-60.
89. Adolph J, Dehnert I, Fischer JF, Wenz W. Results of hyposensitization with bee and wasp venom. Z Erkr Atmungsorgane 1986; 166:119-24.
90. Oude Elberink JN, de Monchy JG, van der HS, Guyatt GH, Dubois AE. Venom immunotherapy improves health-related quality of life in patients allergic to yellow jacket venom. J Allergy Clin Immunol 2002; 110:174-82.
91. Oude Elberink JN, van der HS, Guyatt GH, Dubois AE. Immunotherapy improves health-related quality of life of adult patients with dermal reactions following yellow jacket stings. Clin Exp Allergy 2009; 39:883-9.
92. Ramirez DA, Londono S, Evans R III Adverse reactions to venom immunotherapy. Ann Allergy 1981; 47:435-9.
93. Chipps BE, Valentine MD, Kagey-Sobotka A, Schuberth KC, Lichtenstein LM. Diagnosis and treatment of anaphylactic reactions to Hymenoptera stings in children. J Pediatr 1980; 97:177-84.
94. Lockey RF, Turkeltaub PC, Olive ES, Hubbard JM, Baird-Warren IA, Bukantz SC. The Hymenoptera venom study. III: safety of venom immunotherapy. J Allergy Clin Immunol 1990; 86:775-80.
95. Wyss M, Scheitlin T, Stadler BM, Wuthrich B. Immunotherapy with aluminum hydroxide adsorbed insect venom extracts (Alutard SQ): immunologic and clinical results of a prospective study over 3 years. Allergy 1993; 48:81-6.
96. Diwakar L, Noorani S, Huissoon AP, Frew AJ, Krishna MT. Practice of venom immunotherapy in the United Kingdom: a national audit and review of literature. Clin Exp Allergy 2008; 38:1651-8.
97. Laurent J, Smiejan JM, Bloch-Morot E, Herman D. Safety of Hymenoptera venom rush immunotherapy. Allergy 1997; 52:94-6.
98. Sturm G, Kranke B, Rudolph C, Aberer W. Rush Hymenoptera venom immunotherapy: a safe and practical protocol for high-risk patients. J Allergy Clin Immunol 2002; 110:928-33.
99. Brehler R, Wolf H, Kutting B, Schnitker J, Luger T. Safety of a two-day ultrarush insect venom immunotherapy protocol in comparison with protocols of longer duration and involving a larger number of injections. J Allergy Clin Immunol 2000; 105:1231-5.
100. Birnbaum J, Ramadour M, Magnan A, Vervloet D. Hymenoptera ultra-rush venom immunotherapy (210min): a safety study and risk factors. Clin Exp Allergy 2003; 33:58-64.
101. Reimers A, Hari Y, Muller U. Reduction of side-effects from ultrarush immunotherapy with honeybee venom by pretreatment with fexofenadine: a double-blind, placebo-controlled trial. Allergy 2000; 55:484-8.
102. Berchtold E, Maibach R, Muller U. Reduction of side effects from rush-immunotherapy with honey bee venom by pretreatment with terfenadine. Clin Exp Allergy 1992; 22:59-65.
103. Bernstein DI, Mittman RJ, Kagen SL, Korbee L, Enrione M, Bernstein IL. Clinical and immunologic studies of rapid venom immunotherapy in Hymenoptera-sensitive patients. J Allergy Clin Immunol 1989; 84:951-9.
104. Bernstein JA, Kagen SL, Bernstein DI, Bernstein IL. Rapid venom immunotherapy is safe for routine use in the treatment of patients with Hymenoptera anaphylaxis. Ann Allergy 1994; 73:423-8.
105. Golden DB, Valentine MD, Kagey-Sobotka A, Lichtenstein LM. Regimens of Hymenoptera venom immunotherapy. Ann Intern Med 1980; 92:620-4.
106. Birnbaum J, Charpin D, Vervloet D. Rapid Hymenoptera venom immunotherapy: comparative safety of three protocols. Clin Exp Allergy 1993; 23:226-30.
107. Mosbech H, Muller U. Side-effects of insect venom immunotherapy: results from an EAACI multicenter study. European Academy of Allergology and Clinical Immunology. Allergy 2000; 55:1005-10.
108. Bonifazi F, Jutel M, Bilo BM, Birnbaum J, Muller U. Prevention and treatment of hymenoptera venom allergy: guidelines for clinical practice. Allergy 2005; 60:1459-70.
109. Rueff F, Wenderoth A, Przybilla B. Patients still reacting to a sting challenge while receiving conventional Hymenoptera venom immunotherapy are protected by increased venom doses. J Allergy Clin Immunol 2001; 108:1027-32.
110. Brockow K, Kiehn M, Riethmuller C, Vieluf D, Berger J, Ring J. Efficacy of antihistamine pretreatment in the prevention of adverse reactions to Hymenoptera immunotherapy: a prospective, randomized, placebo-controlled trial. J Allergy Clin Immunol 1997; 100:458-63.
111. Muller UR, Jutel M, Reimers A et al. Clinical and immunologic effects of H1 antihistamine preventive medication during honeybee venom immunotherapy. J Allergy Clin Immunol 2008; 122:1001-7.
112. Lang DM, Alpern MB, Visintainer PF, Smith ST. Increased risk for anaphylactoid reaction from contrast media in patients on beta-adrenergic blockers or with asthma. Ann Intern Med 1991; 115:270-6.
113. Allergen immunotherapy: a practice parameter second update. J Allergy Clin Immunol 2007; 120:S25-85.
114. Muller UR, Haeberli G. Use of beta-blockers during immunotherapy for Hymenoptera venom allergy. J Allergy Clin Immunol 2005; 115:606-10.
115. Sherman MS, Lazar EJ, Eichacker P. A bronchodilator action of glucagon. J Allergy Clin Immunol 1988; 81:908-11.
116. Thomas M, Crawford I. Best evidence topic report. Glucagon infusion in refractory anaphylactic shock in patients on beta-blockers. Emerg Med J 2005; 22:272-3.
117. Ober AI, MacLean JA, Hannaway PJ. Life-threatening anaphylaxis to venom immunotherapy in a patient taking an angiotensin-converting enzyme inhibitor. J Allergy Clin Immunol 2003; 112:1008-9.
118. White KM, England RW. Safety of angiotensin-converting enzyme inhibitors while receiving venom immunotherapy. Ann Allergy Asthma Immunol 2008; 101:426-30.
119. Schulze J, Rose M, Zielen S. Beekeepers anaphylaxis: successful immunotherapy covered by omalizumab. Allergy 2007; 62:963-4.
120. Kontou-Fili K. High omalizumab dose controls recurrent reactions to venom immunotherapy in indolent systemic mastocytosis. Allergy 2008; 63:376-8.
121. Niedoszytko M, de MJ, van Doormaal JJ, Jassem E, Oude Elberink JN. Mastocytosis and insect venom allergy: diagnosis, safety and efficacy of venom immunotherapy. Allergy 2009; 64:1237-45.
122. Golden DB, Kagey-Sobotka A, Lichtenstein LM. Survey of patients after discontinuing venom immunotherapy. J Allergy Clin Immunol 2000; 105:385-90.
123. Haugaard L, Norregaard OF, Dahl R. In-hospital sting challenge in insect venom-allergic patients after stopping venom immunotherapy. J Allergy Clin Immunol 1991; 87:699-702.
124. Lerch E, Muller UR. Long-term protection after stopping venom immunotherapy: results of re-stings in 200 patients. J Allergy Clin Immunol 1998; 101:606-12.
125. Golden DB. Fatal insect allergy after discontinuation of venom immunotherapy. J Allergy Clin Immunol 2001; 107:925-6.
126. Dubois AE. Investigational and clinical use of the sting challenge. Curr Opin Allergy Clin Immunol 2003; 3:283-5.
127. Schuetze GE, Forster J, Hauk PJ, Friedl K, Kuehr J. Bee-venom allergy in children: long-term predictive value of standardized challenge tests. Pediatr Allergy Immunol 2002; 13:18-23.
128. Oude Elberink JN, de Monchy JG, Kors JW, van Doormaal JJ, Dubois AE. Fatal anaphylaxis after a yellow jacket sting, despite venom immunotherapy, in two patients with mastocytosis. J Allergy Clin Immunol 1997; 99:153-4.
129. Reimers A, Mueller U. Fatal outcome of a Vespula sting in a patient with mastocytosis after specific immunotherapy with honey bee venom. Allergy Clin Immunol Int J WAO Org 2005; 17 (Suppl. 1):69-70.
130. Light WC. Insect sting fatality 9 years after venom treatment (venom allergy, fatality). J Allergy Clin Immunol 2001; 107:925.
131. Steiss JO, Jodicke B, Lindemann H. A modified ultrarush insect venom immunotherapy protocol for children. Allergy Asthma Proc 2006; 27:148-50.
132. Ewan PW. New insight into immunological mechanisms of venom immunotherapy. Curr Opin Allergy Clin Immunol 2001; 1:367-74.
133. Akdis CA, Blaser K. IL-10-induced anergy in peripheral T cell and reactivation by microenvironmental cytokines: two key steps in specific immunotherapy. FASEB J 1999; 13:603-9.
134. Akdis CA, Blesken T, Akdis M, Wuthrich B, Blaser K. Role of interleukin 10 in specific immunotherapy. J Clin Invest 1998; 102:98-106.
135. Nasser SM, Ying S, Meng Q, Kay AB, Ewan PW. Interleukin-10 levels increase in cutaneous biopsies of patients undergoing wasp venom immunotherapy. Eur J Immunol 2001; 31:3704-13.
136. Nouri-Aria KT, Wachholz PA, Francis JN et al. Grass pollen immunotherapy induces mucosal and peripheral IL-10 responses and blocking IgG activity. J Immunol 2004; 172:3252-9.
137. Akdis CA, Joss A, Akdis M, Faith A, Blaser K. A molecular basis for T cell suppression by IL-10: CD28-associated IL-10 receptor inhibits CD28 tyrosine phosphorylation and phosphatidylinositol 3-kinase binding. FASEB J 2000; 14:1666-8.
138. Joss A, Akdis M, Faith A, Blaser K, Akdis CA. IL-10 directly acts on T cells by specifically altering the CD28 co-stimulation pathway. Eur J Immunol 2000; 30:1683-90.
139. Bellinghausen I, Metz G, Enk AH, Christmann S, Knop J, Saloga J. Insect venom immunotherapy induces interleukin-10 production and a Th2-to-Th1 shift, and changes surface marker expression in venom-allergic subjects. Eur J Immunol 1997; 27:1131-9.
140. McHugh S, Deighton J, Rifkin I, Ewan P. Kinetics and functional implications of Th1 and Th2 cytokine production following activation of peripheral blood mononuclear cells in primary culture. Eur J Immunol 1996; 26:1260-5.
141. Royer B, Varadaradjalou S, Saas P, Guillosson JJ, Kantelip JP, Arock M. Inhibition of IgE-induced activation of human mast cells by IL-10. Clin Exp Allergy 2001; 31:694-704.
142. Ewan PW, Deighton J, Wilson AB, Lachmann PJ. Venom-specific IgG antibodies in bee and wasp allergy: lack of correlation with protection from stings. Clin Exp Allergy 1993; 23:647-60.
143. Wilson AB, Deighton J, Lachmann PJ, Ewan PW. A comparative study of IgG subclass antibodies in patients allergic to wasp or bee venom. Allergy 1994; 49:272-80.
144. Blaauw PJ, Smithuis LO. The evaluation of the common diagnostic methods of hypersensitivity for bee and yellow jacket venom by means of an in-hospital insect sting. J Allergy Clin Immunol 1985; 75:556-62.
145. Michils A, Baldassarre S, Ledent C, Mairesse M, Gossart B, Duchateau J. Early effect of ultrarush venom immunotherapy on the IgG antibody response. Allergy 2000; 55:455-62.
146. Engel T, Heinig JH, Weeke ER. Prognosis of patients reacting with urticaria to insect sting. Results of an in-hospital sting challenge. Allergy 1988; 43:289-93.
147. Kampelmacher MJ, van der Zwan JC. Provocation test with a living insect as a diagnostic tool in systemic reactions to bee and wasp venom: a prospective study with emphasis on the clinical aspects. Clin Allergy 1987; 17:317-27.
148. Parker JL, Santrach PJ, Dahlberg MJ, Yunginger JW. Evaluation of Hymenoptera-sting sensitivity with deliberate sting challenges: inadequacy of present diagnostic methods. J Allergy Clin Immunol 1982; 69:200-7.
149. Savliwala MN, Reisman RE. Studies of the natural history of stinging-insect allergy: long-term follow-up of patients without immunotherapy. J Allergy Clin Immunol 1987; 80:741-5.
150. Schuberth KC, Lichtenstein LM, Kagey-Sobotka A, Szklo M, Kwiterovich KA, Valentine MD. Epidemiologic study of insect allergy in children. II. Effect of accidental stings in allergic children. J Pediatr 1983; 102:361-5.
151. Lantner R, Reisman RE. Clinical and immunologic features and subsequent course of patients with severe insect-sting anaphylaxis. J Allergy Clin Immunol 1989; 84:900-6.
152. Ewan PW, Stewart AG. A prospective study of systemic reactions to venom immunotherapy (VIT). Clin Exp Allergy 1993; 23 (Suppl. 1):82; Abstract.
153. Youlten LJ, Atkinson BA, Lee TH. The incidence and nature of adverse reactions to injection immunotherapy in bee and wasp venom allergy. Clin Exp Allergy 1995; 25:159-65.
154. Muller U, Hari Y, Berchtold E. Premedication with antihistamines may enhance efficacy of specific-allergen immunotherapy. J Allergy Clin Immunol 2001; 107:81-6.